Advertisement

Idera Pharmaceuticals Inc.’s (Nasdaq: IDRA) stock dropped more than 5 percent Monday, following the company’s announcement that it would delay the launch of a clinical trial on its drug candidate for hepatitis C, due to toxicology study results on rodents that showed instances of atypical proliferation of a type of white blood cells, called lymphocytes. High levels of lymphocytes are generally associated with viral infections.

The company announced its decision on Friday, when the markets were closed.

SOURCE

Advertisement
Advertisement